Tanespimycin

Generic Name: Tanespimycin

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₃₁H_₄₃N_₃O_₈

CAS Number: 75747-14-7

Unique Ingredient Identifier: 4GY0AVT3L4

Background: Tanespimycin, manufactured by Conforma Therapeutics is under development as a small molecule inhibitor of heat shock protein 90 (HSP90). It is developed for the treatment of several types of cancer, solid tumors or chronic myelogenous leukemia.

Indication: Investigated for use/treatment in leukemia (myeloid) and solid tumors.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Clinical Trial of Continuing Treatment for Patients Who Have Participated on a Prior Protocol Investigating Tanespimycin

Phase 2

Completed

Conditions: Advanced Malignancies

Interventions: Drug: Tanespimycin

First Posted Date: 2008-10-24

Last Posted Date: 2015-10-12

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 6

Registration Number: NCT00779428

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Clinical Trial of the Combination of Trastuzumab (Herceptin) and Tanespimycin in Patients With Solid Tumors and Her2 Positive Metastatic Breast Cancer That Have Previously Failed Herceptin

Phase 1

Completed

Conditions: Breast Cancer
Solid Tumors

Interventions: Drug: Tanespimycin

First Posted Date: 2008-10-16

Last Posted Date: 2015-11-04

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 25

Registration Number: NCT00773344

Locations: 🇺🇸
Premiere Oncology Of Arizona, Scottsdale, Arizona, United States
🇺🇸
Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Stage IV Pancreatic Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of the Pancreas
Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer

Interventions: Drug: gemcitabine hydrochloride
Drug: tanespimycin

First Posted Date: 2007-12-20

Last Posted Date: 2014-07-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 21

Registration Number: NCT00577889

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

Phase 3

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Tanespimycin
Drug: Bortezomib

First Posted Date: 2007-10-19

Last Posted Date: 2011-06-28

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 31

Registration Number: NCT00546780

Locations: 🇺🇸
Comprehensive Blood And Cancer Center, Bakersfield, California, United States
🇺🇸
Rocky Mountain Cancer Centers, Denver, Colorado, United States
🇺🇸
Moores Ucsd Cancer Center, La Jolla, California, United States

and more 16 locations

A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

Interventions: Drug: tanespimycin
Drug: Bortezomib

First Posted Date: 2007-08-09

Last Posted Date: 2015-12-07

Lead Sponsor: Bristol-Myers Squibb

Target Recruit Count: 22

Registration Number: NCT00514371

Locations: 🇺🇸
Local Institution, Columbia, South Carolina, United States

PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma

Phase 1

Terminated

Conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma
Anaplastic Large Cell Lymphoma
Angioimmunoblastic T-cell Lymphoma
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Intraocular Lymphoma
Nodal Marginal Zone B-cell Lymphoma
Post-transplant Lymphoproliferative Disorder
Recurrent Adult Burkitt Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Adult Diffuse Mixed Cell Lymphoma

Interventions: Drug: tanespimycin
Drug: belinostat
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2006-07-20

Last Posted Date: 2013-05-16

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 36

Registration Number: NCT00354185

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis

Phase 2

Completed

Conditions: Leukemia
Nonneoplastic Condition
Chronic Myeloproliferative Disorders
Precancerous Condition
Lymphoma

First Posted Date: 2005-08-19

Last Posted Date: 2012-03-15

Lead Sponsor: National Institutes of Health Clinical Center (CC)

Target Recruit Count: 37

Registration Number: NCT00132015

Locations: 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office, Bethesda, Maryland, United States
🇺🇸
NCI - Center for Cancer Research, Bethesda, Maryland, United States

17-AAG and Sorafenib in Treating Patients With Unresectable or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: sorafenib tosylate
Drug: tanespimycin
Other: laboratory biomarker analysis
Other: pharmacological study
Procedure: magnetic resonance imaging

First Posted Date: 2005-07-21

Last Posted Date: 2014-06-17

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 54

Registration Number: NCT00121264

Locations: 🇺🇸
Barbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States

17-AAG and Irinotecan in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Phase 1

Completed

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: tanespimycin
Drug: irinotecan hydrochloride

First Posted Date: 2005-07-13

Last Posted Date: 2013-06-04

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 48

Registration Number: NCT00119236

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Stage IV Prostate Cancer
Recurrent Prostate Cancer

Interventions: Drug: tanespimycin
Other: laboratory biomarker analysis

First Posted Date: 2005-07-11

Last Posted Date: 2017-04-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 17

Registration Number: NCT00118092

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy